• Zachary N Litvack, Georg Norén, Prakash B Chougule, and Zhen Zheng.
• New England Gamma Knife Center and Department of Clinical Neurosciences (Neurosurgery), Brown Medical School /Rhode Island Hospital, Providence, Rhode Island 02903, USA.
• Neurosurg Focus. 2003 May 15; 14 (5): e3.

ObjectThe goal of this retrospective study was to define the rates of preservation of functional hearing and growth control of vestibular schwannomas (VS) treated by gamma knife surgery (GKS) involving a consistent 12-Gy prescription dose.MethodsOne hundred thirty-four patients with unilateral VS underwent GKS between 1994 and 2000. The mean magnetic resonance (MR) imaging follow-up period was 31.7 months (maximum 72 months), and the mean audiometry follow-up interval was 26.3 months (maximum 60 months). The mean marginal dose was 12 +/- 0.6 Gy. The mean maximum dose delivered to the tumor center was 25.4 Gy (range 17.4-34.3 Gy). The tumor control rate, defined as no change or a reduction in size at last follow up, was 96.7%. Of the patients studied, 97.7% remained free from the need to undergo tumor resection. Overall functional hearing preservation was 61.7%; the preservation rate for intracanalicular tumors was 63.6%, for those with an intracranial diameter less than 1.5 cm it was 54.5%, for those between 1.5 and 3 cm it was 68.2%, and for those larger than 3 cm it was 33.3%. Early in the series, three patients (2.2%) developed temporary facial weakness (House-Brackmann Grade II-III) in the posttreatment period, but this resolved within a few weeks. No case of facial weakness occurred after 1996.ConclusionsThe authors demonstrated the efficacy, safety, and in many ways, the advantage of GKS over microsurgery for VS. Patients harboring tumors 3 cm or smaller in intracranial diameter, regardless of their age and medical condition, should be given the option of undergoing GKS as primary treatment.

20 keywords...

hide…